Solid state forms of apalutamide
Disclosed are solid state forms of Apalutamide and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof.
1. A solid state form of Apalutamide selected from:
(A) crystalline form T13, which is characterized by data selected from one or more of the following:
(i) a PXRD pattern having peaks at 13.8, 17.1, 18.3, 22.4 and 26.8 degrees 2-theta±0.1 degrees 2-theta;
(ii) a PXRD pattern as depicted in FIG. 13 , alternatively a PXRD pattern as depicted in FIG. 18 ;
(iii) a PXRD pattern having peaks at 13.8, 17.1, 18.3, 22.4 and 26.8 degrees 2-theta±0.1 degrees 2-theta, and also having one, two or three additional peaks at 13.3, 16.2 and 21.4 degrees 2-theta±0.1 degrees 2-theta;
or
(B) crystalline form T11, which is characterized by data selected from one or more of the following:
(i) a PXRD pattern having peaks at 15.3, 15.6, 18.9, 19.4, 22.9, and 28.7 degrees 2-theta±0.1 degrees 2-theta;
(ii) a PXRD pattern as depicted in FIG. 11 ;
(iii) a PXRD pattern having peaks at 15.3, 15.6, 18.9, 19.4, 22.9, and 28.7 degrees 2-theta±0.1 degrees 2-theta, and also having one, two, three, or four additional peaks at 16.8, 24.1, 25.8, and 28.2 degrees 2-theta±0.1 degrees 2-theta.
2. A solid state form of Apalutamide
crystalline form T2, which is characterized by data selected from one or more of the following:
(i) a PXRD pattern having peaks at 4.5, 6.9, 13.6, 15.8, 19.8, 24.2 and 26.1 degrees 2-theta±0.1 degrees 2-theta;
(ii) a PXRD pattern as depicted in FIG. 2 ;
(iii) a PXRD pattern having peaks at 4.5, 6.9, 13.6, 15.8, 19.8, 24.2 and 26.1 degrees 2-theta±0.1 degrees 2-theta, and also having one, two, three or four additional peaks at 9.0, 10.5, 18.3 and 22.4 degrees 2-theta±0.1 degrees 2-theta.
3. Crystalline form T13 of Apalutamide according to claim 1 , which is characterized by data selected from one or more of the following:
(i) a PXRD pattern having peaks at 13.8, 17.1, 18.3, 22.4 and 26.8 degrees 2-theta±0.1 degrees 2-theta;
(ii) a PXRD pattern as depicted in FIG. 13 , alternatively a PXRD pattern as depicted in FIG. 18 ;
(iii) a PXRD pattern having peaks at 13.8, 17.1, 18.3, 22.4 and 26.8 degrees 2-theta±0.1 degrees 2-theta, and also having one, two or three additional peaks at 13.3, 16.2 and 21.4 degrees 2-theta±0.1 degrees 2-theta.
4. Crystalline form T11 of Apalutamide according to claim 1 , which is characterized by data selected from one or more of the following:
(i) a PXRD pattern having peaks at 15.3, 15.6, 18.9, 19.4, 22.9, and 28.7 degrees 2-theta±0.1 degrees 2-theta;
(ii) a PXRD pattern as depicted in FIG. 11 ;
(iii) a PXRD pattern having peaks at 15.3, 15.6, 18.9, 19.4, 22.9, and 28.7 degrees 2-theta±0.1 degrees 2-theta, and also having one, two, three, or four additional peaks at 16.8, 24.1, 25.8, and 28.2 degrees 2-theta±0.1 degrees 2-theta.
5. Crystalline form T2 of Apalutamide according to claim 2 , which is characterized by
a PXRD pattern having peaks at 4.5, 6.9, 13.6, 15.8, 19.8, 24.2 and 26.1 degrees 2-theta±0.1 degrees 2-theta.
6. The solid state form of Apalutamide according to claim 3 , wherein crystalline form T13 is a monohydrate.
7. The solid state form of Apalutamide according to claim 4 , wherein crystalline form T11 is a dihydrate having about 6.5% to about 7.5% (w/w) of water as depicted in KF.
8. The solid state form of Apalutamide according to claim 5 , wherein crystalline form T2 is a 2-butanol solvate.
9. A solid state form of Apalutamide according to claim 1 , which is polymorphically pure.
10. A pharmaceutical composition or formulation comprising a solid state form of Apalutamide or combinations thereof according to claim 1 .
11. A pharmaceutical composition or formulation according to claim 10 comprising at least one pharmaceutically acceptable excipient.
12. A process for preparing a pharmaceutical composition or formulation according to claim 10 comprising combining any one or combination of the solid state forms of Apalutamide and at least one pharmaceutically acceptable excipient.
13. A process for preparing other solid state forms of Apalutamide comprising preparing any one or combination of the solid state forms of Apalutamide according to claim 9 and converting them to other crystalline forms of Apalutamide.
14. A method of treating prostate cancer, comprising administering a therapeutically effective amount of any one or combination of the solid state forms of Apalutamide according to claim 1 to a subject suffering from prostate cancer, or otherwise in need of the treatment.
15. A pharmaceutical composition or formulation comprising a solid state form of Apalutamide or combinations thereof according to claim 2 .
16. A pharmaceutical composition or formulation according to claim 15 comprising at least one pharmaceutically acceptable excipient.
17. A process for preparing a pharmaceutical composition or formulation according to claim 15 comprising combining any one or combination of the solid state forms of Apalutamide and at least one pharmaceutically acceptable excipient.
18. A method of treating prostate cancer, comprising administering a therapeutically effective amount of any one or combination of the solid state forms of Apalutamide according to claim 2 to a subject suffering from prostate cancer, or otherwise in need of the treatment.